• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国家卫生经济评估指南中折扣的系统评价:医疗保健价值的影响。

A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications.

机构信息

Health Economics & Market Access, Boston Scientific, Marlborough, MA 01752, USA.

Department of Pharmacy Practice & Administrative Sciences, University of Cincinnati, James L Winkle College of Pharmacy, Cincinnati, OH 45229, USA.

出版信息

J Comp Eff Res. 2023 Feb;12(2):e220167. doi: 10.2217/cer-2022-0167. Epub 2022 Dec 7.

DOI:10.2217/cer-2022-0167
PMID:36476014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10288966/
Abstract

This review summarizes the discounting approaches recommended in current economic evaluation (EE) guidelines for healthcare programs and interventions. A systematic review of EE guidelines for healthcare, published up to July 2022, was conducted. A total of 52 EE guidelines were reviewed. The majority of these guidelines recommend equal discounting (80.8%) rather than differential discounting (9.6%). The rationale for equal discounting includes recommendations by the government, consistency with other countries, and economic development. However, the rationale for differential discounting is based on the interest in short-term government bonds and anticipated budget changes. This review demonstrates variation in both discounting approaches and rates across EE guidelines and underscores the need for a global consensus on discounting approaches.

摘要

本综述总结了当前医疗保健计划和干预措施的经济评估(EE)指南中推荐的折扣方法。对截至 2022 年 7 月发布的医疗保健 EE 指南进行了系统回顾。共审查了 52 项 EE 指南。其中大多数指南建议采用平等折扣(80.8%)而非差异折扣(9.6%)。平等折扣的理由包括政府的建议、与其他国家的一致性以及经济发展。然而,差异折扣的理由基于对短期政府债券的兴趣和预期预算变化。本综述表明,EE 指南中的折扣方法和利率存在差异,强调需要就折扣方法达成全球共识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e1/10288966/978e76f8e03c/cer-12-220167-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e1/10288966/64e79a6c95ff/cer-12-220167-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e1/10288966/eaef9f860e8c/cer-12-220167-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e1/10288966/978e76f8e03c/cer-12-220167-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e1/10288966/64e79a6c95ff/cer-12-220167-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e1/10288966/eaef9f860e8c/cer-12-220167-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e1/10288966/978e76f8e03c/cer-12-220167-g3.jpg

相似文献

1
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications.国家卫生经济评估指南中折扣的系统评价:医疗保健价值的影响。
J Comp Eff Res. 2023 Feb;12(2):e220167. doi: 10.2217/cer-2022-0167. Epub 2022 Dec 7.
2
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.腹腔镜手术治疗结直肠癌的临床疗效与成本效益:系统评价与经济学评估
Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. doi: 10.3310/hta10450.
8
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.巴雷特食管的监测:通过系统评价、专家研讨会和经济模型探索不确定性
Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080.
9
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.促红细胞生成素α、促红细胞生成素β和达比加群酯治疗癌症相关性贫血(尤其是癌症治疗所致贫血)的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130.
10
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.依那西普和英夫利昔单抗治疗银屑病关节炎:系统评价与经济学评估
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.

引用本文的文献

1
Economic Burden of TB Deaths in India (2021): A Retrospective Cross-sectional Study.印度结核病死亡的经济负担(2021年):一项回顾性横断面研究。
Open Forum Infect Dis. 2025 Jul 21;12(8):ofaf433. doi: 10.1093/ofid/ofaf433. eCollection 2025 Aug.
2
Identifying characteristics for a cost-effective psoriatic arthritis biomarker test: a development-focused health technology assessment.确定具有成本效益的银屑病关节炎生物标志物检测的特征:一项以开发为重点的卫生技术评估
Int J Technol Assess Health Care. 2025 May 23;41(1):e29. doi: 10.1017/S0266462325000091.
3
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force.

本文引用的文献

1
A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.一篇关于卫生经济评价指南中官方贴现率的全面综述:趋势和根源。
Eur J Health Econ. 2022 Dec;23(9):1577-1590. doi: 10.1007/s10198-022-01445-x. Epub 2022 Mar 2.
2
Economic evaluation guidelines in low- and middle-income countries: a systematic review.经济评估指南在中低收入国家:系统评价。
Int J Technol Assess Health Care. 2021 Dec 21;38(1):e1. doi: 10.1017/S0266462321000659.
3
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.
卫生技术评估指南制定的良好实践:卫生技术评估国际组织、HTAsiaLink及药物经济学与结果研究国际协会特别工作组的报告
Int J Technol Assess Health Care. 2025 Jan 6;40(1):e74. doi: 10.1017/S0266462324004719.
4
Impact of perioperative diagnostic tools on clinical outcomes and cost-effectiveness in parathyroid surgery: a decision model-based analysis.围手术期诊断工具对甲状旁腺手术临床结局和成本效益的影响:基于决策模型的分析。
BMJ Open. 2024 Sep 5;14(9):e082901. doi: 10.1136/bmjopen-2023-082901.
5
Estimated reduction in obesity prevalence and costs of a 20% and 30% ad valorem excise tax to sugar-sweetened beverages in Brazil: A modeling study.巴西对含糖饮料征收20%和30%从价消费税预计带来的肥胖患病率降低及成本变化:一项建模研究。
PLoS Med. 2024 Jul 17;21(7):e1004399. doi: 10.1371/journal.pmed.1004399. eCollection 2024 Jul.
6
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.基于一项国际随机 3 期临床试验评估肿瘤浸润淋巴细胞治疗晚期黑色素瘤的成本效果。
J Immunother Cancer. 2024 Mar 26;12(3):e008372. doi: 10.1136/jitc-2023-008372.
7
Cost associated with diverting ostomy after rectal cancer surgery: a transnational analysis.直肠癌手术后造口改道的相关成本:一项跨国分析。
Surg Endosc. 2023 Oct;37(10):7759-7766. doi: 10.1007/s00464-023-10300-w. Epub 2023 Aug 14.
PRISMA 2020 解释和说明:系统评价报告的更新指南和范例。
BMJ. 2021 Mar 29;372:n160. doi: 10.1136/bmj.n160.
4
Critical Review of European Health-Economic Guidelines for the Health Technology Assessment of Medical Devices.欧洲医疗器械卫生技术评估健康经济指南的批判性综述
Front Med (Lausanne). 2019 Nov 29;6:278. doi: 10.3389/fmed.2019.00278. eCollection 2019.
5
National Health Care Spending In 2018: Growth Driven By Accelerations In Medicare And Private Insurance Spending.2018 年国家医疗保健支出:医疗保险和私人保险支出加速推动增长。
Health Aff (Millwood). 2020 Jan;39(1):8-17. doi: 10.1377/hlthaff.2019.01451. Epub 2019 Dec 5.
6
On discount rates for economic evaluations in global health.关于全球健康经济评估中的贴现率。
Health Policy Plan. 2020 Feb 1;35(1):107-114. doi: 10.1093/heapol/czz127.
7
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt.埃及药物经济学评价报告建议。
Value Health Reg Issues. 2013 Sep-Oct;2(2):319-327. doi: 10.1016/j.vhri.2013.06.014. Epub 2013 Sep 13.
8
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.《健康与医疗领域成本效益分析的实施、方法学实践和报告推荐:第二版》。
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
9
From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.从良好到更佳:荷兰医疗保健经济评估新指南
Pharmacoeconomics. 2016 Nov;34(11):1071-1074. doi: 10.1007/s40273-016-0431-y.
10
What is the impact of disease prevalence upon health technology assessment?疾病流行率对卫生技术评估有什么影响?
Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):853-65. doi: 10.1016/j.bpg.2013.08.018. Epub 2013 Sep 27.